{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:46:44Z","timestamp":1791953204892,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Orion Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01055-2","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:11:59Z","timestamp":1791911519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Towards a Better Definition of Patient-Centered Therapeutic Strategy of Parkinson\u2019s Disease: An Opinion Paper"],"prefix":"10.1007","author":[{"given":"Heinz","family":"Reichmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallol Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodor","family":"Danaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Foltynie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Jes\u00fas Maestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valtteri","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Katzenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"L\u00f3pez Manzanares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pagonabarraga Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Santens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Santos Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tamburin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"3","key":"1055_CR1","doi-asserted-by":"publisher","first-page":"afag063","DOI":"10.1093\/ageing\/afag063","volume":"55","author":"D Pourzinal","year":"2026","unstructured":"Pourzinal D, Brooks D, Sriram D, et al. Best practice guidelines for the diagnosis, evaluation, and management of cognitive disorders in Parkinson\u2019s disease. Age Ageing. 2026;55(3):afag063.","journal-title":"Age Ageing"},{"issue":"3","key":"1055_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/mdc3.13962","volume":"11","author":"D Brinker","year":"2024","unstructured":"Brinker D, Smilowska K, Paschen S, et al. How to use the new European Academy of Neurology\/Movement Disorder Society European Section guideline for invasive therapies in Parkinson\u2019s disease. Mov Disord Clin Pract. 2024;11(3):209\u201319.","journal-title":"Mov Disord Clin Pract"},{"key":"1055_CR3","doi-asserted-by":"publisher","DOI":"10.5014\/ajot.2022.763001","author":"J Wood","year":"2022","unstructured":"Wood J, Henderson W, Foster ER. Occupational therapy practice guidelines for people with Parkinson\u2019s disease. Am J Occup Ther. 2022. https:\/\/doi.org\/10.5014\/ajot.2022.763001.","journal-title":"Am J Occup Ther"},{"issue":"2","key":"1055_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3233\/JPD-212881","volume":"12","author":"LM Carroll","year":"2022","unstructured":"Carroll LM, Morris ME, O\u2019Connor WT. Evidence-based aquatic therapy guidelines for Parkinson\u2019s disease: an international consensus study. J Parkinsons Dis. 2022;12(2):621\u201337.","journal-title":"J Parkinsons Dis"},{"issue":"20","key":"1055_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","volume":"97","author":"T Pringsheim","year":"2021","unstructured":"Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN Guideline Subcommittee. Neurology. 2021;97(20):942\u201357.","journal-title":"Neurology"},{"issue":"5","key":"1055_CR6","first-page":"358","volume":"14","author":"RA Nuvolini","year":"2025","unstructured":"Nuvolini RA, Silva KGD, Freitas TB, et al. Exergame-based program and conventional physiotherapy based on core areas of the European guideline similarly improve gait and cognition in people with Parkinson\u2019s disease: randomized clinical trial. Games Health J. 2025;14(5):358\u201368.","journal-title":"Games Health J"},{"key":"1055_CR7","doi-asserted-by":"publisher","DOI":"10.1055\/s-0045-1802962","author":"DP Maia","year":"2025","unstructured":"Maia DP, Cury RG, Brand\u00e3o PRP, et al. Guidelines for Parkinson\u2019s disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology\u2014non-motor symptoms. Arq Neuropsiquiatr. 2025. https:\/\/doi.org\/10.1055\/s-0045-1802962.","journal-title":"Arq Neuropsiquiatr"},{"issue":"3","key":"1055_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00415-025-12915-6","volume":"272","author":"R Reese","year":"2025","unstructured":"Reese R, Koeglsperger T, Schrader C, et al. Invasive therapies for Parkinson\u2019s disease: an adapted excerpt from the guidelines of the German Society of Neurology. J Neurol. 2025;272(3):219.","journal-title":"J Neurol"},{"issue":"4","key":"1055_CR9","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1002\/pri.2114","volume":"29","author":"CS Figueiredo","year":"2024","unstructured":"Figueiredo CS, Pinto C, Bevilacqua IP, et al. Teleassessment using five times sit-to-stand test in older adults with and without Parkinson\u2019s disease: guidelines and barriers. Physiother Res Int. 2024;29(4):e2114.","journal-title":"Physiother Res Int"},{"issue":"11","key":"1055_CR10","doi-asserted-by":"publisher","first-page":"7330","DOI":"10.1007\/s00415-024-12503-0","volume":"271","author":"E Kalbe","year":"2024","unstructured":"Kalbe E, Folkerts AK, Witt K, et al. German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson\u2019s disease: new spotlights on diagnostic procedures and non-pharmacological interventions. J Neurol. 2024;271(11):7330\u201357.","journal-title":"J Neurol"},{"issue":"12","key":"1055_CR11","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1007\/s00415-024-12576-x","volume":"271","author":"K Witt","year":"2024","unstructured":"Witt K, Levin J, van Eimeren T, et al. Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations\u2014guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology. J Neurol. 2024;271(12):7402\u201321.","journal-title":"J Neurol"},{"issue":"1","key":"1055_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42466-024-00325-4","volume":"6","author":"G H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger G, German Parkinson\u2019s Guidelines Committee; Claudia Trenkwalder. Diagnosis and treatment of Parkinson\u2019s disease (guideline of the German Society for Neurology). Neurol Res Pract. 2024;6(1):30.","journal-title":"Neurol Res Pract"},{"issue":"10","key":"1055_CR13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/mdc3.13860","volume":"10","author":"R Camicioli","year":"2023","unstructured":"Camicioli R, Morris ME, Pieruccini-Faria F, et al. Prevention of falls in Parkinson\u2019s disease: guidelines and gaps. Mov Disord Clin Pract. 2023;10(10):1459\u201369.","journal-title":"Mov Disord Clin Pract"},{"issue":"3","key":"1055_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1089\/g4h.2022.0039","volume":"12","author":"KG Da Silva","year":"2023","unstructured":"Da Silva KG, Nuvolini RA, Bacha JMR, et al. Comparison of the effects of an exergame-based program with conventional physiotherapy protocol based on core areas of the European guideline on postural control, functional mobility, and quality of life in patients with Parkinson\u2019s disease: randomized clinical trial. Games Health J. 2023;12(3):228\u201341.","journal-title":"Games Health J"},{"issue":"3","key":"1055_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1590\/0004-282x-anp-2021-0219","volume":"80","author":"RA Saba","year":"2022","unstructured":"Saba RA, Maia DP, Cardoso FEC, et al. Guidelines for Parkinson\u2019s disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology\u2014motor symptoms. Arq Neuropsiquiatr. 2022;80(3):316\u201329.","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"1055_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/NRE-210181","volume":"50","author":"K Medijainen","year":"2022","unstructured":"Medijainen K, P\u00e4\u00e4suke M, Lukmann A, Taba P. Structured guideline-based physiotherapy reduces difficulties in activities of daily living in Parkinson\u2019s disease. NeuroRehabilitation. 2022;50(1):47\u201356.","journal-title":"NeuroRehabilitation"},{"issue":"2","key":"1055_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40520-020-01612-1","volume":"33","author":"C Martignon","year":"2021","unstructured":"Martignon C, Pedrinolla A, Ruzzante F, et al. Guidelines on exercise testing and prescription for patients at different stages of Parkinson\u2019s disease. Aging Clin Exp Res. 2021;33(2):221\u201346.","journal-title":"Aging Clin Exp Res"},{"key":"1055_CR18","doi-asserted-by":"publisher","first-page":"108067","DOI":"10.1016\/j.parkreldis.2025.108067","volume":"140","author":"E Houston","year":"2025","unstructured":"Houston E, Boyd S, Iyer V, Boyd J, Gupta D. The need for developing consensus-based guidelines in assessing Parkinson\u2019s disease laterality. Parkinsonism Relat Disord. 2025;140:108067.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1055_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00415-024-12730-5","volume":"272","author":"A Fanciulli","year":"2025","unstructured":"Fanciulli A, Sixel-D\u00f6ring F, Buhmann C, et al. Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson\u2019s disease: guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology. J Neurol. 2025;272(1):90.","journal-title":"J Neurol"},{"issue":"11","key":"1055_CR20","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1007\/s00415-024-12687-5","volume":"271","author":"F Hopfner","year":"2024","unstructured":"Hopfner F, H\u00f6glinger G, German Parkinson\u2019s Guidelines Group, Trenkwalder C. Definition and diagnosis of Parkinson\u2019s disease: guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology. J Neurol. 2024;271(11):7102\u201319.","journal-title":"J Neurol"},{"issue":"11","key":"1055_CR21","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.1007\/s00415-024-12632-6","volume":"271","author":"M H\u00f6llerhage","year":"2024","unstructured":"H\u00f6llerhage M, Becktepe J, Classen J, et al. Pharmacotherapy of motor symptoms in early and mid-stage Parkinson\u2019s disease: guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology. J Neurol. 2024;271(11):7071\u2013101.","journal-title":"J Neurol"},{"issue":"10","key":"1055_CR22","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.1007\/s00415-024-12649-x","volume":"271","author":"M P\u00f6tter-Nerger","year":"2024","unstructured":"P\u00f6tter-Nerger M, L\u00f6hle M, H\u00f6glinger G, German Parkinson\u2018s Guideline Group. Akinetic crisis and withdrawal syndromes: guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology. J Neurol. 2024;271(10):6485\u201393.","journal-title":"J Neurol"},{"issue":"12","key":"1055_CR23","doi-asserted-by":"publisher","first-page":"7377","DOI":"10.1007\/s00415-024-12546-3","volume":"271","author":"L T\u00f6nges","year":"2024","unstructured":"T\u00f6nges L, Buhmann C, Eggers C, et al. Guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology (Deutsche Gesellschaft f\u00fcr Neurologie): concepts of care. J Neurol. 2024;271(12):7377\u201386.","journal-title":"J Neurol"},{"issue":"12","key":"1055_CR24","doi-asserted-by":"publisher","first-page":"7387","DOI":"10.1007\/s00415-024-12502-1","volume":"271","author":"U Walter","year":"2024","unstructured":"Walter U, Loewenbr\u00fcck KF, Dodel R, et al. Systematic review-based guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology: diagnostic use of transcranial sonography. J Neurol. 2024;271(12):7387\u2013401.","journal-title":"J Neurol"},{"issue":"3","key":"1055_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/mdc3.13942","volume":"11","author":"P Stamatelos","year":"2024","unstructured":"Stamatelos P, Economou A, Yannis G, Stefanis L, Papageorgiou SG. Parkinson\u2019s disease and driving fitness: a systematic review of the existing guidelines. Mov Disord Clin Pract. 2024;11(3):198\u2013208.","journal-title":"Mov Disord Clin Pract"},{"key":"1055_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6667339","author":"K Rosqvist","year":"2023","unstructured":"Rosqvist K, Odin P. Compliance with national and international guidelines in the treatment of nonmotor symptoms in late-stage Parkinson\u2019s disease. Parkinsons Dis. 2023. https:\/\/doi.org\/10.1155\/2023\/6667339.","journal-title":"Parkinsons Dis"},{"issue":"7","key":"1055_CR27","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology\/Movement Disorder Society\u2014European Section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies. Mov Disord. 2022;37(7):1360\u201374.","journal-title":"Mov Disord"},{"issue":"9","key":"1055_CR28","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1111\/ene.15386","volume":"29","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology\/Movement Disorder Society\u2014European Section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies. Eur J Neurol. 2022;29(9):2580\u201395.","journal-title":"Eur J Neurol"},{"issue":"6","key":"1055_CR29","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3233\/JPD-212986","volume":"12","author":"PA Salles","year":"2022","unstructured":"Salles PA, Liao J, Shuaib U, Mata IF, Fernandez HH. A review on response to device-aided therapies used in monogenic parkinsonism and GBA variants carriers: a need for guidelines and comparative studies. J Parkinsons Dis. 2022;12(6):1703\u201325.","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"1055_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/jpm12050730","volume":"12","author":"M Hoskovcov\u00e1","year":"2022","unstructured":"Hoskovcov\u00e1 M, R\u016f\u017ei\u010dka E, G\u00e1l O. The category of conventional physiotherapy: the case of Parkinson\u2019s disease guidelines. J Pers Med. 2022;12(5):730.","journal-title":"J Pers Med"},{"issue":"4","key":"1055_CR31","doi-asserted-by":"publisher","first-page":"pzab302","DOI":"10.1093\/ptj\/pzab302","volume":"102","author":"JA Osborne","year":"2022","unstructured":"Osborne JA, Botkin R, Colon-Semenza C, et al. Physical therapist management of Parkinson disease: a clinical practice guideline from the American Physical Therapy Association. Phys Ther. 2022;102(4):pzab302.","journal-title":"Phys Ther"},{"issue":"2","key":"1055_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/ane.13434","volume":"144","author":"JM Norlin","year":"2021","unstructured":"Norlin JM, Willis M, Persson U, et al. Swedish guidelines for device-aided therapies in Parkinson\u2019s disease\u2014economic evaluation and implementation. Acta Neurol Scand. 2021;144(2):170\u20138.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1055_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00415-020-10132-x","volume":"268","author":"JMM Domingos","year":"2021","unstructured":"Domingos JMM, Capato TTC, Almeida LRS, et al. The European Physiotherapy Guideline for Parkinson\u2019s disease: translation for non-English speaking countries. J Neurol. 2021;268(1):214\u20138.","journal-title":"J Neurol"},{"key":"1055_CR34","doi-asserted-by":"publisher","unstructured":"Osborne JA, Botkin R, Colon-Semenza C, DeAngelis TR, Gallardo OG, Kosakowski H, Martello J, Pradham S, Rafferty M, Readinger JL. Editor\u2019s Note on: Physical therapist management of Parkinson disease: a clinical practice guideline from the American Physical Therapy Association. 2022;102(4):pzab302. https:\/\/doi.org\/10.1093\/ptj\/pzab302. Phys Ther. 2024;104(8):pzae031.","DOI":"10.1093\/ptj\/pzab302"},{"issue":"1","key":"1055_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jphys.2022.11.002","volume":"69","author":"R Gosselink","year":"2023","unstructured":"Gosselink R. Appraisal of clinical practice guideline from the American Physical Therapy Association (APTA): physical therapist management of Parkinson disease. J Physiother. 2023;69(1):60.","journal-title":"J Physiother"},{"issue":"3","key":"1055_CR36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40520-020-01770-2","volume":"33","author":"C Martignon","year":"2021","unstructured":"Martignon C, Pedrinolla A, Ruzzante F, et al. Reply to the letter \u201cWhat does characterize exercise guidelines for Parkinson\u2019s disease?\u201d Aging Clin Exp Res. 2021;33(3):677\u20138.","journal-title":"Aging Clin Exp Res"},{"issue":"9","key":"1055_CR37","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s40520-020-01748-0","volume":"33","author":"FA Barbieri","year":"2021","unstructured":"Barbieri FA, Kalva-Filho CA, Torriani-Pasin C. What does characterize exercise guidelines for Parkinson\u2019s disease? Aging Clin Exp Res. 2021;33(9):2611\u20132.","journal-title":"Aging Clin Exp Res"},{"issue":"4","key":"1055_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00415-019-09181-8","volume":"267","author":"T Kuusim\u00e4ki","year":"2020","unstructured":"Kuusim\u00e4ki T, Korpela J, Pekkonen E, et al. Deep brain stimulation for monogenic Parkinson\u2019s disease: a systematic review. J Neurol. 2020;267(4):883\u201397.","journal-title":"J Neurol"},{"key":"1055_CR39","doi-asserted-by":"publisher","first-page":"635494","DOI":"10.3389\/fpsyt.2021.635494","volume":"12","author":"JF Zhang","year":"2021","unstructured":"Zhang JF, Wang XX, Feng Y, et al. Impulse control disorders in Parkinson\u2019s disease: epidemiology, pathogenesis and therapeutic strategies. Front Psychiatry. 2021;12:635494.","journal-title":"Front Psychiatry"},{"issue":"5","key":"1055_CR40","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/ana.25581","volume":"86","author":"J Mar\u00edn-Lahoz","year":"2019","unstructured":"Mar\u00edn-Lahoz J, Sampedro F, Martinez-Horta S, et al. Depression as a risk factor for impulse control disorders in Parkinson disease. Ann Neurol. 2019;86(5):762\u20139.","journal-title":"Ann Neurol"},{"issue":"2","key":"1055_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/mds.29700","volume":"39","author":"I Debove","year":"2024","unstructured":"Debove I, Paschen S, Amstutz D, et al. Management of impulse control and related disorders in Parkinson\u2019s disease: an expert consensus. Mov Disord. 2024;39(2):235\u201348.","journal-title":"Mov Disord"},{"issue":"10","key":"1055_CR42","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","volume":"24","author":"D Weintraub","year":"2009","unstructured":"Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease. Mov Disord. 2009;24(10):1461\u20137.","journal-title":"Mov Disord"},{"issue":"3","key":"1055_CR43","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","volume":"91","author":"JC Corvol","year":"2018","unstructured":"Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91(3):e189\u2013201.","journal-title":"Neurology"},{"issue":"3","key":"1055_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1212\/WNL.0000000000005806","volume":"91","author":"LS Boylan","year":"2018","unstructured":"Boylan LS, Kosti\u0107 VS. Don\u2019t ask, don\u2019t tell: impulse control disorders in PD. Neurology. 2018;91(3):107\u20138.","journal-title":"Neurology"},{"issue":"4","key":"1055_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/jnnp-2016-315277","volume":"88","author":"A Antonini","year":"2017","unstructured":"Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2017;88(4):317\u201324.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1055_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/brainsci16010043","volume":"16","author":"L Ricciardi","year":"2025","unstructured":"Ricciardi L, Ishihara B, Gonz\u00e1lez-Herrero B, et al. Holistic care clinic for people with Parkinson\u2019s disease: outcome from a newly developed service. Brain Sci. 2025;16(1):43.","journal-title":"Brain Sci"},{"key":"1055_CR47","doi-asserted-by":"publisher","unstructured":"Dallapiazza RF,\u00a0De Vloo P,\u00a0Fomenko A,\u00a0et al. Parkinson\u2019s disease: pathogenesis and clinical aspects. Chapter 8: Considerations for patient and target selection in deep brain stimulation surgery for Parkinson\u2019s disease. https:\/\/doi.org\/10.15586\/codonpublications.parkinsonsdisease.2018.ch8.","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch8"},{"issue":"1","key":"1055_CR48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1877718X251399958","volume":"16","author":"MS Okun","year":"2026","unstructured":"Okun MS, Bloem BR, Dorsey ER. The Parkinson\u2019s universe: a person-centered care model for Parkinson\u2019s disease. J Parkinsons Dis. 2026;16(1):192\u20135.","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"1055_CR49","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/NRE-246004","volume":"54","author":"C Cordani","year":"2024","unstructured":"Cordani C, Mosconi B. What type of physical exercise works best to improve movement and quality of life for people with Parkinson\u2019s disease?\u2014A Cochrane review summary with commentary. NeuroRehabilitation. 2024;54(4):699\u2013702.","journal-title":"NeuroRehabilitation"},{"key":"1055_CR50","unstructured":"The Parkinson's Companion. https:\/\/theparkinsonscompanion.org. Accessed 30 July 2026."},{"key":"1055_CR51","unstructured":"King\u2019s College Hospital NHS Foundation Trust. Ten years of patient group to support Parkinson\u2019s research. https:\/\/www.kch.nhs.uk\/news\/ten-years-of-patient-group-to-support-parkinsons-research\/. Accessed 30 July 2026."},{"issue":"12","key":"1055_CR52","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/brainsci14121244","volume":"14","author":"D Santos-Garc\u00eda","year":"2024","unstructured":"Santos-Garc\u00eda D, L\u00f3pez-Manzanares L, Muro I, et al. Use of the MNCD classification to monitor clinical stage and response to levodopa\u2013entacapone\u2013carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease. Brain Sci. 2024;14(12):1244.","journal-title":"Brain Sci"},{"issue":"7","key":"1055_CR53","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Martinez-Martin P, Schapira AHV, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord. 2006;21(7):916\u201323.","journal-title":"Mov Disord"},{"issue":"1","key":"1055_CR54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41531-024-00699-x","volume":"10","author":"V Dzialas","year":"2024","unstructured":"Dzialas V, Hoenig MC, Prange S, et al. Structural underpinnings and long-term effects of resilience in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2024;10(1):94.","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"1055_CR55","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/mdc3.70381","volume":"13","author":"I Subramanian","year":"2026","unstructured":"Subramanian I, Ricciardi L, Schrag A, et al. A holistic wellness prescription for Parkinson\u2019s disease: evidence-based perspectives and unmet needs. Mov Disord Clin Pract. 2026;13(3):631\u201346.","journal-title":"Mov Disord Clin Pract"},{"key":"1055_CR56","doi-asserted-by":"publisher","first-page":"105838","DOI":"10.1016\/j.parkreldis.2023.105838","volume":"116","author":"B McDaniels","year":"2023","unstructured":"McDaniels B, Pontone GM, Mathur S, Subramanian I. Staying hidden: the burden of stigma in PD. Parkinsonism Relat Disord. 2023;116:105838.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1055_CR57","doi-asserted-by":"publisher","first-page":"e200613","DOI":"10.1212\/CPJ.0000000000200613","volume":"16","author":"MA Hillen","year":"2026","unstructured":"Hillen MA, Kurpershoek E, Huisman MHB, et al. Clinician communication about uncertainty during Parkinson disease diagnostic consultations. Neurol Clin Pract. 2026;16(3):e200613.","journal-title":"Neurol Clin Pract"},{"issue":"9","key":"1055_CR58","doi-asserted-by":"publisher","first-page":"e213499","DOI":"10.1212\/WNL.0000000000213499","volume":"104","author":"V R\u00e4ty","year":"2025","unstructured":"R\u00e4ty V, Kuusim\u00e4ki T, Majuri J, et al. Stability and accuracy of a diagnosis of Parkinson disease over 10\u00a0years. Neurology. 2025;104(9):e213499.","journal-title":"Neurology"},{"issue":"5","key":"1055_CR59","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/14737175.2025.2485337","volume":"25","author":"L Rigon","year":"2025","unstructured":"Rigon L, Fogliano C, Chaudhuri KR, et al. Managing impulse control and related behavioral disorders in Parkinson\u2019s disease: where we are in 2025? Expert Rev Neurother. 2025;25(5):537\u201354.","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"1055_CR60","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s40265-026-02327-9","volume":"86","author":"S Leiter","year":"2026","unstructured":"Leiter S, Mahlknecht P, Poewe W. Recent developments in the drug treatment of Parkinson\u2019s disease. Drugs. 2026;86(8):1231\u201360.","journal-title":"Drugs"},{"issue":"5","key":"1055_CR61","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/mds.20041","volume":"19","author":"NA Leopold","year":"2004","unstructured":"Leopold NA, Polansky M, Hurka MA. Drug adherence in Parkinson\u2019s disease. Mov Disord. 2004;19(5):513\u20137.","journal-title":"Mov Disord"},{"issue":"11","key":"1055_CR62","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/mds.20602","volume":"20","author":"KA Grosset","year":"2005","unstructured":"Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson\u2019s disease. Mov Disord. 2005;20(11):1502\u20137.","journal-title":"Mov Disord"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01055-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:07:17Z","timestamp":1791950837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01055-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":62,"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01055-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"21 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Apart from the honoraria related to participation in the Delphi questionnaire and discussion related to the present article, some of the co-authors declare potential conflict of interests as follows. Heinz Reichmann has been acting on advisory boards, gave lectures, and received research grants from Abbott, AbbVie, Bayer Health Care, Bial, Boehringer Ingelheim, Britannia, Cephalon, Desitin, Eisai, GSK, Lundbeck, Medtronic, Merck-Serono, Novartis, Orion, Pfizer, TEVA, UCB Pharma, Valeant, and Zambon. Angelo Antonini has received compensation for consultancy and speaker-related activities from AbbVie, Britannia, Teva, Zambon, Bial, Roche, Stada, Ever Pharma, Novartis, Bayer, Orion Pharma, Ferrer. Stefano Tamburin has received compensation for consultancy and speaker-related activities from AbbVie, Alfasigma, Bial and Viatris. Diego Santos Garc\u00eda has received honoraria for educational presentations and\u00a0advice service by AbbVie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, Italfarmaco, Teva, Arch\u00edmedes, Esteve, Stada, Orion Pharma, a financial compensation for INIBIC\/Fundaci\u00f3n Professor Novoa Santos in relation to activity as PI in phase\u00a02 to phase\u00a04 clinical trials for Parkinson\u2019s disease and other movement disorders, compensation for Fundaci\u00f3n Degen in relation to different projects, and grants from the \u201cFundaci\u00f3n Professor Novoa Santos\u201d as a result of the \u201cConvocatoria de ayudas para la realizaci\u00f3n de proyectos de investigaci\u00f3n para grupos emergentes y asociados del inibic (2023\/2024)\u201d. Valtteri Kaasinen has received compensation for consultancy and speaker-related activities from AbbVie, Lundbeck, Bial, Orion Pharma, Eisai and Nordic Infucare AB. David Devos\u00a0has received PHRC grants from the French Ministry of Health (PHRC & ANR), European Grants (H2020 and Coen) and research funding from the ARSLA charity, France Parkinson charity, Fondation Credit Agricole, Fondation de France, Cure Parkinson Trust, and served on advisory boards and\/or as a consultant, and\/or given lectures for AbbVie, Alterity, Orkyn, Air Liquide, Elivie, Home perf, Apopharma, Lundbeck, Ever Pharma, Medtronic, Boston Scientific, Ever Pharma, Boston Scientific, UCB Pharma, Eisai, Servier, PTC Therapeutics, Orion Pharma, AB Science, Alzprotect, Cajal Neuroscience, Zambon, Brain & Mind. He holds stakes in InBrain Pharma and Invenis biotherapies. Thomas Foltynie has received grants from National Institute of Health Research, Edmond J Safra Foundation, Michael J Fox Foundation, John Black Charitable Foundation, Cure Parkinson\u2019s, Parkinson\u2019s UK, Gatsby Foundation, Innovate UK, Janet Owens Research Fellowship, Van Andel Research Institute and Defeat MSA. He has served on Advisory Boards for AC Immune, Peptron, AbbVie, Eli Lilly, Bluerock, Bayer and Bial. Olivier Rascol has received compensation for consultancy and speaker-related activities from Bial, Biogen, Britannia, Conter, GE Healthcare, Ionis, LGD Nuvamid, Lundbeck, Merz, Neuralight, Neuroderm, ONO Pharma, Orion Pharma, PD Neurotechnology, Roche Therapeutics, Sanofi, Supernus, Thelonius Mind, Takeda, Teva, UCB, Zambon, and scientific grants from Agence Nationale de la Recherche (ANR), CHU de Toulouse, CURE PARKINSON, European Commission (H2020, Horizon Europe) France-Parkinson, MJFox Foundation, French Ministry of Health (Programme Hospitalier de Recherche Clinique), and French Ministry of Research (Programme Investissement Avenir and France 2030). Olivier Rascol is a member of the Editorial Board of\n                      Neurology and Therapy\n                      . Olivier Rascol was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. J\u00fcrgen Winkler has received compensation for consultancy and speaker-related activities from Bial, Desitin, Lundbeck, and Zambon. Lydia L\u00f3pez Manzanares received compensations for advisory services, consultancy, research grants and\/or speaker honoraria from AbbVie, Abbott, Bial, Britannia, Esteve, Italfarmaco, Lundbeck, Merz, Roche, Stada, Teva and Zambon. Javier Pagonabarraga Mora has received compensation for consultancy and speaker-related activities from AbbVie, Bial, Medtronic, Zambon, Merz, and Esteve. Silvia Jes\u00fas Maestre has received honoraria for consulting and speaker activities from AbbVie, Zambon, Bial, Italfarmaco, Ever Pharma, Orion, Merz, and Esteve. Kallol Ray Chaudhuri is a member of the Editorial Board of\n                      Neurology and Therapy\n                      . Kallol Ray Chaudhuri was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Teodor Danaila, Wolfgang H. Jost, and Patrick Santens have nothing relevant to declare.","order":1,"name":"Ethics","label":"Conflict of Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Delphi exercise was done by collecting answers from the co-authors, and not from patients or anonymous health care providers. It was a discussion technique aimed at reaching a consensus. No new data or studies were considered, just the co-author expertise and the existing literature and, for this reason, no ethical approval was required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}